Celecoxib induces apoptosis in COX-2 deficient human gastric cancer cells through Akt/GSK3β/NAG-1 pathway

Cancer Letters

Volumn 251, Issue 2, 2007, Pages 268-277

  Pang, Rui Ping ^a   Zhou, Jia Guo ^b   Zeng, Zhi Rong ^a   Li, Xiao Yan ^b   Chen, Wei ^a   Chen, Min Hu ^a   Hu, Pin Jin ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

Akt; Apoptosis; Celecoxib; Gastric cancer cell; GSK3 ; NAG 1

Indexed keywords

2 (2,4 DICHLOROPHENYL) 3 (1 METHYL 3 INDOLYL)MALEIMIDE; CASPASE 3; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN GSK3BETA; PROTEIN KINASE; PROTEIN KINASE B; SERINE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DRUG CAPSULE; DRUG INHIBITION; DRUG MECHANISM; GENE; GENE SILENCING; HUMAN; HUMAN CELL; NAG 1 GENE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN DEPHOSPHORYLATION; PROTEIN PHOSPHORYLATION; STOMACH CANCER; UPREGULATION; WESTERN BLOTTING;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APOPTOSIS; CASPASE 3; CELL LINE, TUMOR; COLLAGEN TYPE XI; CYCLOOXYGENASE 2; CYTOKINES; GENE EXPRESSION; HUMANS; MEMBRANE PROTEINS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PYRAZOLES; REPRESSOR PROTEINS; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; SULFONAMIDES;

EID: 34247623111     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2006.11.032     Document Type: Article

References (49)

1. Meric J.B., Rottey S., Olaussen K., Soria J.C., Khayat D., Rixe O., and Spano J.P. Cyclooxygenase-2 as a target for anticancer drug development. Crit. Rev. Oncol. Hematol. 59 (2006) 51-64
2. Tjiu J.W., Liao Y.H., Lin S.J., Huang Y.L., Tsai W.L., Chu C.Y., Kuo M.L., and Jee S.H. Cyclooxygenase-2 overexpression in human basal cell carcinoma cell line increases antiapoptosis, angiogenesis, and tumorigenesis. J. Invest. Dermatol. 126 (2006) 1143-1151
3. Liu C.H., Chang S.H., Narko K., Trifan O.C., Wu M.T., Smith E., Haudenschild C., Lane T.F., and Hla T. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J. Biol. Chem. 276 (2001) 18563-18569
4. Lu S., Yu G., Zhu Y., and Archer M.C. Cyclooxygenase-2 overexpression in MCF-10F human breast epithelial cells inhibits proliferation, apoptosis and differentiation, and causes partial transformation. Int. J. Cancer 116 (2005) 847-852
5. Howe L.R., Chang S.H., Tolle K.C., Dillon R., Young L.J., Cardiff R.D., Newman R.A., Yang P., Thaler H.T., Muller W.J., Hudis C., Brown A.M., HIa T., Subbaramaiah K., and Dannenberg A.J. HER2/neu-induced mammary tumorigenesis and angiogenesis are reduced in cyclooxygenase-2 knockout mice. Cancer Res. 65 (2005) 10113-10119
6. Δ716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 87 (1996) 803-809
7. Kashfi K., and Rigas B. Non-COX-2 targets and cancer: expanding the molecular target repertoire of chemoprevention. Biochem. Pharmacol. 70 (2005) 969-986
8. Dannenberg A.J., and Subbaramaiah K. Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell 4 (2003) 431-436
9. Steinbach G., Lynch P.M., Phillips R.K., Wallace M.H., Hawk E., Gordon G.B., Wakabayashi N., Saunders B., Shen Y., Fujimura T., Su L.K., and Levin B. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med. 342 (2000) 1946-1952
10. Giardiello F.M., Yang V.W., Hylind L.M., Krush A.J., Petersen G.M., Trimbath J.D., Piantadosi S., Garrett E., Geiman D.E., Hubbard W., Offerhaus G.J., and Hamilton S.R. Primary chemoprevention of familial adenomatous polyposis with sulindac. N. Engl. J. Med. (2002) 1054-1059
11. Cruz-Correa M., Hylind L.M., Romans K.E., Booker S.V., and Giardiello F.M. Long-term treatment with sulindac in familial adenomatous polyposis: a prospective cohort study. Gastroenterology 122 (2002) 641-645
12. Phillips R.K., Wallace M.H., Lynch P.M., Hawk E., Gordon G.B., Saunders B.P., Wakabayashi N., Shen Y., Zimmerman S., Godio L., Rodrigues-Bigas M., Su L.K., Sherman J., Kelloff G., Levin B., and Steinbach G. PAF study groupl. A randomised, double-blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut 50 (2002) 857-860
13. Hanif R., Pittas A., Feng Y., Koutsos M.I., Qiao L., Staiano-Coico L., Shiff S.I., and Rigas B. Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem. Pharmacol. 52 (1996) 237-245
14. Elder D.J.E., Halton D.E., Hague A., and Paraskeva C. Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug independence from COX-2 protein expression. Clin. Cancer Res. 3 (1997) 1679-1683
15. Waskewich C., Blumenthal R.D., Li H., Stein R., Goldenberg D.M., and Burton J. Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines. Cancer Res. 62 (2002) 2029-2033
16. Piazza G.A., Alberts D.S., Hixson L.J., Paranka N.S., Li H., Finn T., Bogert C., Guillen J.M., Brendel K., Gross P.H., Sperl G., Ritchie J., Burt R.W., Ellsworth L., Ahnen D.J., and Pamukcu R. Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res. 57 (1997) 2909-2915
17. Goluboff E.T., Shabsigh A., Saidi J.A., Weinstein I.B., Mitra N., Heitjan D., Piazza G.A., Pamukcu R., Buttyan R., and Olsson C.A. (sulindac sulfone) suppresses growth of human prostate cancer in a nude mouse xenograft model by increasing apoptosis. Urology 53 (1999) 440-445
18. Song X., Lin H.P., Johnson A.J., Tseng P.H., Yang Y.T., Kulp S.K., and Chen C.S. Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells. J. Natl. Cancer Inst. 94 (2002) 585-591
19. Schwenger P., Bellosta P., Vietor I., Basilico C., Skolnik E.Y., and Vilcek J. Sodium salicylate induces apoptosis via p38 mitogen-activated protein kinase but inhibits tumor necrosis factor-induced c-Jun N-terminal kinase/stress-activated protein kinase activation. Proc. Natl. Acad. Sci. USA 94 (1997) 2869-2873
20. He T.C., Chan T.A., Vogelstein B., and Kinzler K.W. PPARdelta is an APC regulated target of nonsteroidal anti-inflammatory drugs. Cell 99 (1999) 335-345
21. Shureiqi I., Chen D., Lotan R., Yang P., Newman R.A., Fischer S.M., and Lippman S.M. 15-Lipoxygenase-1 mediates nonsteroidal anti-inflammatory drug-induced apoptosis independently of cyclooxygenase-2 in colon cancer cells. Cancer Res. 60 (2000) 6846-6850
22. Kopp E., and Ghosh S. Inhibition of NF-κB by sodium salicylate and aspirin. Science 265 (1994) 956-959
23. Arico S., Pattingre S., Bauvy C., Gane P., Barbat A., Codogno P., and Ogier-Dens E. Celecoxib induces apoptosis by inhibiting 3-phosphoinositide dependent protein kinase-1 activity in the human colon cancer HT-29 cell line. J. Biol. Chem. 277 (2002) 27613-27621
24. Baek S.J., Kim K.S., Nixon J.B., Wilson L.C., and Eling T.E. Cyclooxygenase inhibitors regulate the expression of a TGF-beta superfamily member that has proapoptotic and antitumorigenic activities. Mol. Pharmacol. 59 (2001) 901-908
25. Jang T.J., Kang H.J., Kim J.R., and Yang C.H. Non-steroidal anti-inflammatory drug activated gene (NAG-1) expression is closely related to death receptor-4 and -5 induction, which may explain sulindac sulfide induced gastric cancer cell apoptosis. Carcinogenesis. 25 (2004) 1853-1858
26. Baek S.J., Kim J.S., Moore S.M., Lee S.H., Martinez J., and Eling T.E. Cyclooxygenase inhibitors induce the expression of the tumor suppressor gene EGR-1, which results in the up-regulation of NAG-1, an antitumorigenic protein. Mol. Pharmacol. 67 (2005) 356-364
27. Kim K.S., Baek S.J., Flake G.P., Loftin C.D., Calvo B.F., and Eling T.E. Expression and regulation of nonsteroidal anti-inflammatory drug activated gene (NAG-1) in human and mouse tissue. Gastroenterology 122 (2002) 1388-1398
28. Liu T., Bauskin A.R., Zaunders J., Brown D.A., Pankhurst S., Russell P.J., and Breit S.N. Macrophage inhibitory cytokine 1 reduces cell adhesion and induces apoptosis in prostate cancer cells. Cancer Res. 63 (2003) 5034-5340
29. Yamaguchi K., Lee S.-H., Eling T.E., and Baek S.J. Identification of nonsteroidal anti-inflammatory drug-activated gene(NAG-1) as a noval downstream target of phosphatidylinositol 3-kinase/AKT/GSK-3β pathway. J. Biol. Chem. 279 (2004) 49617-49623
30. Shim M., and Eling T.E. Protein kinase C-dependent regulation of NAG-1/placental bone morphogenic protein/MIC-1 expression in LNCaP prostate carcinoma cells. J. Biol. Chem. 280 (2005) 18636-18642
31. Hu P.J., Yu J., Zeng Z.R., Leung W.K., Lin H.L., Tang B.D., Bai A.H.C., and Sung J.J.Y. Chemoprevention of gastric cancer by celecoxib in rats. Gut 53 (2004) 195-200
32. Zhu J., Huang J.W., Tseng P.H., Yang Y.T., Fowble J., Shiau C.W., Shaw Y.J., Kulp S.K., and Chen C.S. From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors. Cancer Res. 64 (2004) 4309-4318
33. Brautigam L., Vetter G., Tegeder I., Heinkele G., and Geisslinger G. Determination of Celecoxib in human plasma and rat microdialysis samples by liquid chromatography tandem mass spectrometry. J. Chromatogr. Biomed. Appl. 261 (2001) 203-212
34. Zhou J.G., Ren J.L., Qiu Q.Y., He H., and Guan Y.Y. Regulation of intracellular Cl- concentration through volume-regulated ClC-3 chloride channel in A10 vascular smooth muscle cells. J. Biol. Chem. 280 (2005) 7301-7308
35. Xu X., Sakon M., Nagano H., Hiraoka N., Yamamoto H., Hayashi N., Dono K., Nakamori S., Umeshita K., Ito Y., Matsuura N., and Monden M. Akt2 expression correlates with prognosis of human hepatocellular carcinoma. Oncol. Rep. 11 (2004) 25-32
36. Roy H.K., Olusola B.F., Clemens D.L., Karolski W.J., Ratashak A., Lynch H.T., and Smyrk T.C. AKT proto-oncogene overexpression is an early event during sporadic colon carcinogenesis. Carcinogenesis. 23 (2002) 201-205
37. Yamamoto S., Tomita Y., Hoshida Y., Morooka T., Nagano H., Dono K., Umeshita K., Sakon M., Ishikawa O., Ohigashi H., Nakamori S., M M., and Aozasa K. Prognostic significance of activated Akt expression in pancreatic ductal adenocarcinoma. Clin. Cancer Res. 10 (2004) 2846-2850
38. (WAF/CIP) expression and androgen-independent growth in prostate cancer cells. Int. J. Oncol. 28 (2006) 245-251
39. Ang K.L., Shi D.L., Keong W.W., and Epstein R.J. Upregulated Akt signaling adjacent to gastric cancers: implications for screening and chemoprevention. Cancer Lett. 225 (2005) 53-59
40. Basu G.D., Pathangey L.B., Tinder T.L., Gendler S.J., and Mukherjee P. Mechanisms underlying the growth inhibitory effects of the cyclooxygenase-2 inhibitor celecoxib in human breast cancer cells. Breast Cancer Res. 7 (2005) R422-R435
41. Kulp S.K., Yang Y.T., Hung C.C., Chen K.F., Lai J.P., Tseng P.H., Fowble J.W., Ward P.J., and Chen C.S. 3-phosphoinositide-dependent protein kinase-1/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells. Cancer Res. 64 (2004) 1444-1451
42. Wu T., Leng J., Han C., and Demetris A.J. The cyclooxygenase-2 inhibitor celecoxib blocks phosphorylation of Akt and induces apoptosis in human cholangiocarcinoma cells. Mol. Cancer Ther. 3 (2004) 299-307
43. Zhang Z., Lai G.H., and Sirica A.F. Celecoxib-induced apoptosis in rat cholangiocarcinoma cells mediated by Akt inactivation and Bax translocation. Hepatology 39 (2004) 1028-1037
44. Beurel E., Kornprobst M., Blivet-Van Eggelpoel M.J., Ruiz-Ruiz C., Cadoret A., Capeau J., and Desbois-Mouthon C. GSK-3beta inhibition by lithium confers resistance to chemotherapy-induced apoptosis through the repression of CD95 (Fas/APO-1) expression. Exp. Cell Res. 300 (2004) 354-364
45. Liu S., Yu S., Hasegawa Y., Lapushin R., Xu H.J., Woodgett J.R., Mills G.B., and Fang X. Glycogen synthase kinase 3beta is a negative regulator of growth factor-induced activation of the c-Jun N-terminal kinase. J. Biol. Chem. 279 (2004) 51075-51081
46. Lee S.H., Kim J.S., Yamaguchi K., Eling T.E., and Baek S.J. Indole-3-carbinol and 3,3′-diindolylmethane induce expression of NAG-1 in a p53-independent manner. Biochem. Biophys. Res. Commun. 328 (2005) 63-69
47. Baek S.J., Kim J.S., Nixon J.B., DiAugustine R.P., and Eling T.E. Expression of NAG-1, a transforming growth factor-{beta} superfamily member, by troglitazone requires the early growth response gene EGR-1. J. Biol. Chem. 278 (2004) 6883-6892
48. Baek S.J., Wilson L.C., and Eling T.E. Resveratrol enhances the expression of non-steroidal anti-inflammatory drug-activated gene (NAG-1) by increasing the expression of p53. Carcinogenesis. 23 (2002) 425-434
49. Zhang H.N., Zhou J.G., Qiu Q.Y., Ren J.L., and Guan Y.Y. CIC-3 chloride channel prevents apoptosis induced by thapsigargin in PC12 cells. Apoptosis 11 (2006) 327-336